2 5 16 20 25 42 1 Traber

2

5

16

20

25

42

Βιβλιογραφία • • • • • 1. Traber MG. Utilization of vitamin E. Biofactors. 1999; 10(2 -3): 115 -120. (Pub. Med) 2. Traber MG. Vitamin E. In: Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ, eds. Modern Nutrition in Health and Disease. Philadelphia: Lippincott Williams & Wilkiins; 2006: 396 -411. 3. Bruno RS, Leonard SW, Atkinson J, et al. Faster plasma vitamin E disappearance in smokers is normalized by vitamin C supplementation. Free Radic Biol Med. 2006; 40(4): 689 -697. (Pub. Med) 4. Food and Nutrition Board, Institute of Medicine. Vitamin E. Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. Washington D. C. : National Academy Press; 2000: 186 -283. (National Academy Press) 5. Traber MG. Does vitamin E decrease heart attack risk? summary and implications with respect to dietary recommendations. J Nutr. 2001; 131(2): 395 S-397 S. (Pub. Med) 6. Traber MG. Vitamin E regulatory mechanisms. Annu Rev Nutr. 2007; 27: 347 -362. (Pub. Med) 7. Traber MG, Elsner A, Brigelius-Flohe R. Synthetic as compared with natural vitamin E is preferentially excreted as alpha-CEHC in human urine: studies using deuterated alpha-tocopheryl acetates. FEBS Lett. 1998; 437(1 -2): 145 -148. (Pub. Med) 8. Christen S, Woodall AA, Shigenaga MK, Southwell-Keely PT, Duncan MW, Ames BN. gamma-tocopherol traps mutagenic electrophiles such as NO(X) and complements alpha-tocopherol: physiological implications. Proc Natl Acad Sci U S A. 1997; 94(7): 3217 -3222. (Pub. Med) 9. Li D, Saldeen T, Mehta JL. gamma-tocopherol decreases ox-LDL-mediated activation of nuclear factor-kappa. B and apoptosis in human coronary artery endothelial cells. Biochem Biophys Res Commun. 1999; 259(1): 157 -161. (Pub. Med) 10. Helzlsouer KJ, Huang HY, Alberg AJ, et al. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst. 2000; 92(24): 2018 -2023. (Pub. Med) 11. Jiang Q, Christen S, Shigenaga MK, Ames BN. gamma-tocopherol, the major form of vitamin E in the US diet, deserves more attention. Am J Clin Nutr. 2001; 74(6): 714 -722. (Pub. Med) 12. Traber MG. Vitamin E. In: Bowman BA, Russell RM, eds. Present Knowledge in Nutrition. 9 th ed. Volume 1. Washington, D. C. : ILSI Press; 2006: 211 -219. 13. Ford ES, Sowell A. Serum alpha-tocopherol status in the United States population: findings from the Third National Health and Nutrition Examination Survey. Am J Epidemiol. 1999; 150(3): 290 -300. (Pub. Med) 14. Ahuja JK, Goldman JD, Moshfegh AJ. Current status of vitamin E nutriture. Ann N Y Acad Sci. 2004; 1031: 387 -390. (Pub. Med) 15. Maras JE, Bermudez OI, Qiao N, Bakun PJ, Boody-Alter EL, Tucker KL. Intake of alpha-tocopherol is limited among US adults. J Am Diet Assoc. 2004; 104(4): 567 -575. (Pub. Med) 16. Knekt P, Reunanen A, Jarvinen R, Seppanen R, Heliovaara M, Aromaa A. Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am J Epidemiol. 1994; 139(12): 1180 -1189. (Pub. Med) 17. Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, Bostick RM. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med. 1996; 334(18): 1156 -1162. (Pub. Med) 18. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993; 328(20): 1450 -1456. (Pub. Med) 19. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 1993; 328(20): 1444 -1449. (Pub. Med) 20. Cherubini A, Zuliani G, Costantini F, et al. High vitamin E plasma levels and low-density lipoprotein oxidation are associated with the absence of atherosclerosis in octogenarians. J Am Geriatr Soc. 2001; 49(5): 651 -654. (Pub. Med) 49

• • • • • 21. Gale CR, Ashurst HE, Powers HJ, Martyn CN. Antioxidant vitamin status and carotid atherosclerosis in the elderly. Am J Clin Nutr. 2001; 74(3): 402 -408. (Pub. Med) 22. Mc. Quillan BM, Hung J, Beilby JP, Nidorf M, Thompson PL. Antioxidant vitamins and the risk of carotid atherosclerosis. The Perth Carotid Ultrasound Disease Assessment study (CUDAS). J Am Coll Cardiol. 2001; 38(7): 1788 -1794. (Pub. Med) 23. Simon E, Gariepy J, Cogny A, Moatti N, Simon A, Paul JL. Erythrocyte, but not plasma, vitamin E concentration is associated with carotid intima-media thickening in asymptomatic men at risk for cardiovascular disease. Atherosclerosis. 2001; 159(1): 193 -200. (Pub. Med) 24. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005; 294(1): 56 -65. (Pub. Med) 25. Glynn RJ, Ridker PM, Goldhaber SZ, Zee RY, Buring JE. Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study. Circulation. 2007; 116(13): 1497 -1503. (Pub. Med) 26. Traber MG, Frei B, Beckman JS. Vitamin E revisited: do new data validate benefits for chronic disease prevention? Curr Opin Lipidol. 2008; 19(1): 30 -38. (Pub. Med) 27. West AL, Oren GA, Moroi SE. Evidence for the use of nutritional supplements and herbal medicines in common eye diseases. Am J Ophthalmol. 2006; 141(1): 157 -166. (Pub. Med) 28. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for agerelated cataract and vision loss: AREDS report no. 9. Arch Ophthalmol. 2001; 119(10): 1439 -1452. (Pub. Med) 29. Gritz DC, Srinivasan M, Smith SD, et al. The Antioxidants in Prevention of Cataracts Study: effects of antioxidant supplements on cataract progression in South India. Br J Ophthalmol. 2006; 90(7): 847 -851. (Pub. Med) 30. Mc. Neil JJ, Robman L, Tikellis G, Sinclair MI, Mc. Carty CA, Taylor HR. Vitamin E supplementation and cataract: randomized controlled trial. Ophthalmology. 2004; 111(1): 75 -84. (Pub. Med) 31. Teikari JM, Rautalahti M, Haukka J, et al. Incidence of cataract operations in Finnish male smokers unaffected by alpha tocopherol or beta carotene supplements. J Epidemiol Community Health. 1998; 52(7): 468 -472. (Pub. Med) 32. Meydani SN, Meydani M, Blumberg JB, et al. Vitamin E supplementation and in vivo immune response in healthy elderly subjects. A randomized controlled trial. JAMA. 1997; 277(17): 1380 -1386. (Pub. Med) 33. Han SN, Meydani SN. Vitamin E and infectious diseases in the aged. Proc Nutr Soc. 1999; 58(3): 697 -705. (Pub. Med) 34. Meydani SN, Leka LS, Fine BC, et al. Vitamin E and respiratory tract infections in elderly nursing home residents: a randomized controlled trial. JAMA. 2004; 292(7): 828 -836. (Pub. Med) 35. Slatore CG, Littman AJ, Au DH, Satia JA, White E. Long-term use of supplemental multivitamins, vitamin C, vitamin E, and folate does not reduce the risk of lung cancer. Am J Respir Crit Care Med. 2008; 177(5): 524 -530. (Pub. Med) 36. Alkhenizan A, Hafez K. The role of vitamin E in the prevention of cancer: a meta-analysis of randomized controlled trials. Ann Saudi Med. 2007; 27(6): 409 -414. (Pub. Med) 37. Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst. 1998; 90(6): 440 -446. (Pub. Med) 38. Klein EA, Thompson IM, Lippman SM, et al. SELECT: the next prostate cancer prevention trial. Selenum and Vitamin E Cancer Prevention Trial. J Urol. 2001; 166(4): 1311 -1315. (Pub. Med) 39. National Cancer Institute. Review of Prostate Cancer Prevention Study Shows No Benefit for Use of Selenium and Vitamin E Supplements. [Web page]. Available at: http: //www. cancer. gov/newscenter/pressreleases/SELECTresults 2008. 40. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009; 301(1): 39 -51. (Pub. Med) 50

• • • • • 41. Klein EA, Thompson IM, Jr. , Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 306(14): 1549 -1556. (Pub. Med) 42. Azen SP, Qian D, Mack WJ, et al. Effect of supplementary antioxidant vitamin intake on carotid arterial wall intima-media thickness in a controlled clinical trial of cholesterol lowering. Circulation. 1996; 94(10): 2369 -2372. (Pub. Med) 43. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996; 347(9004): 781 -786. (Pub. Med) 44. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 2000; 356(9237): 1213 -1218. (Pub. Med) 45. Rapola JM, Virtamo J, Ripatti S, et al. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet. 1997; 349(9067): 1715 -1720. (Pub. Med) 46. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000; 342(3): 154 -160. (Pub. Med) 47. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999; 354(9177): 447 -455. (Pub. Med) 48. Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA. 2005; 293(11): 1338 -1347. (Pub. Med) 49. Davi G, Ciabattoni G, Consoli A, et al. In vivo formation of 8 -iso-prostaglandin f 2 alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation. 1999; 99(2): 224 -229. (Pub. Med) 50. Paolisso G, D'Amore A, Giugliano D, Ceriello A, Varricchio M, D'Onofrio F. Pharmacologic doses of vitamin E improve insulin action in healthy subjects and non-insulin-dependent diabetic patients. Am J Clin Nutr. 1993; 57(5): 650 -656. (Pub. Med) 51. Paolisso G, Di Maro G, Galzerano D, et al. Pharmacological doses of vitamin E and insulin action in elderly subjects. Am J Clin Nutr. 1994; 59(6): 1291 -1296. (Pub. Med) 52. Paolisso G, D'Amore A, Galzerano D, et al. Daily vitamin E supplements improve metabolic control but not insulin secretion in elderly type II diabetic patients. Diabetes Care. 1993; 16(11): 1433 -1437. (Pub. Med) 53. Reaven PD, Herold DA, Barnett J, Edelman S. Effects of Vitamin E on susceptibility of low-density lipoprotein and low-density lipoprotein subfractions to oxidation and on protein glycation in NIDDM. Diabetes Care. 1995; 18(6): 807 -816. (Pub. Med) 54. Jain SK, Mc. Vie R, Jaramillo JJ, Palmer M, Smith T. Effect of modest vitamin E supplementation on blood glycated hemoglobin and triglyceride levels and red cell indices in type I diabetic patients. J Am Coll Nutr. 1996; 15(5): 458 -461. (Pub. Med) 55. Meydani M. Antioxidants and cognitive function. Nutr Rev. 2001; 59(8 Pt 2): S 75 -80; discussion S 80 -72. 56. Kontush K, Schekatolina S. Vitamin E in neurodegenerative disorders: Alzheimer's disease. Ann N Y Acad Sci. 2004; 1031: 249262. (Pub. Med) 57. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med. 1997; 336(17): 1216 -1222. (Pub. Med) 58. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005; 352(23): 2379 -2388. (Pub. Med) 59. Masaki KH, Losonczy KG, Izmirlian G, et al. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology. 2000; 54(6): 1265 -1272. (Pub. Med) 60. Yu W, Sanders BG, Kline K. RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells involves Bax translocation to mitochondria. Cancer Res. 2003; 63(10): 2483 -2491. (Pub. Med) 51

• • • • • 61. You H, Yu W, Munoz-Medellin D, Brown PH, Sanders BG, Kline K. Role of extracellular signal-regulated kinase pathway in RRRalpha-tocopheryl succinate-induced differentiation of human MDA-MB-435 breast cancer cells. Mol Carcinog. 2002; 33(4): 228 -236. (Pub. Med) 62. Neuzil J, Weber T, Schroder A, et al. Induction of cancer cell apoptosis by alpha-tocopheryl succinate: molecular pathways and structural requirements. FASEB J. 2001; 15(2): 403 -415. (Pub. Med) 63. Brigelius-Flohe R, Kelly FJ, Salonen JT, Neuzil J, Zingg JM, Azzi A. The European perspective on vitamin E: current knowledge and future research. Am J Clin Nutr. 2002; 76(4): 703 -716. (Pub. Med) 64. Weber T, Lu M, Andera L, et al. Vitamin E succinate is a potent novel antineoplastic agent with high selectivity and cooperativity with tumor necrosis factor-related apoptosis-inducing ligand (Apo 2 ligand) in vivo. Clin Cancer Res. 2002; 8(3): 863 -869. (Pub. Med) 65. Malafa MP, Fokum FD, Mowlavi A, Abusief M, King M. Vitamin E inhibits melanoma growth in mice. Surgery. 2002; 131(1): 85 -91. (Pub. Med) 66. Malafa MP, Neitzel LT. Vitamin E succinate promotes breast cancer tumor dormancy. J Surg Res. 2000; 93(1): 163 -170. (Pub. Med) 67. Quin J, Engle D, Litwiller A, et al. Vitamin E succinate decreases lung cancer tumor growth in mice. J Surg Res. 2005; 127(2): 139143. (Pub. Med) 68. Cheeseman KH, Holley AE, Kelly FJ, Wasil M, Hughes L, Burton G. Biokinetics in humans of RRR-alpha-tocopherol: the free phenol, acetate ester, and succinate ester forms of vitamin E. Free Radic Biol Med. 1995; 19(5): 591 -598. (Pub. Med) 69. Hendler SS, Rorvik DR, eds. PDR for Nutritional Supplements. Montvale: Medical Economics Company, Inc; 2001. 70. Berson EL, Rosner B, Sandberg MA, et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol. 1993; 111(6): 761 -772. (Pub. Med) 71. Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005; 142(1): 37 -46. (Pub. Med) 72. Shekelle PG, Morton SC, Jungvig LK, et al. Effect of supplemental vitamin E for the prevention and treatment of cardiovascular disease. J Gen Intern Med. 2004; 19(4): 380 -389. (Pub. Med) 73. Eidelman RS, Hollar D, Hebert PR, Lamas GA, Hennekens CH. Randomized trials of vitamin E in the treatment and prevention of cardiovascular disease. Arch Intern Med. 2004; 164(14): 1552 -1556. (Pub. Med) 74. Abner EL, Schmitt FA, Mendiondo MS, Marcum JL, Kryscio RJ. Vitamin E and all-cause mortality: a meta-analysis. Curr Aging Sci. 2011 Jan 14; [Epub ahead of print] (Pub. Med) 75. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet. 2003; 361(9374): 2017 -2023. (Pub. Med) 76. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007; 297(8): 842 -857. (Pub. Med) 77. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001; 345(22): 1583 -1592. (Pub. Med) 78. Collins R, Peto R, Armitage J. The MRC/BHF Heart Protection Study: preliminary results. Int J Clin Pract. 2002; 56(1): 53 -56. (Pub. Med) 52